Stay updated on MK-3475 in Brain Metastases Clinical Trial
Sign up to get notified when there's something new on the MK-3475 in Brain Metastases Clinical Trial page.

Latest updates to the MK-3475 in Brain Metastases Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe ClinicalTrials.gov record for a completed Phase 2 study of MK-3475 (pembrolizumab) in melanoma and non-small-cell lung cancer patients with untreated brain metastases is now displayed instead of an error page. It includes the study design and outcome measures, participant criteria, results-related publications, and study documents.SummaryDifference50%

- Check18 days agoChange DetectedThe site revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA site-wide notice announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision label on the 403 access-denied page changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision label changed from v3.7.0 to v3.7.1, while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page content is replaced by a 403 Forbidden error page. The page displays a standard header/footer with an access-denied message indicating the resource cannot be accessed.SummaryDifference19%

Stay in the know with updates to MK-3475 in Brain Metastases Clinical Trial
Enter your email address, and we'll notify you when there's something new on the MK-3475 in Brain Metastases Clinical Trial page.